Literature DB >> 15701916

Ximelagatran--promises and concerns.

Victor Gurewich.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701916     DOI: 10.1001/jama.293.6.736

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

Review 1.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 2.  Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke.

Authors:  D J H McCabe; R D Rakhit
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

3.  New treatment options for stroke prevention in atrial fibrillation.

Authors:  Benjamin Rhee; Richard L Page
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-10

4.  Pulmonary embolism: current treatment options.

Authors:  Marc Meysman; Patrick Haentjens
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

Review 5.  Hepatic findings in long-term clinical trials of ximelagatran.

Authors:  William M Lee; Dominique Larrey; Rolf Olsson; James H Lewis; Marianne Keisu; Laurent Auclert; Sunita Sheth
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Antithrombotic therapy in cardiac embolism.

Authors:  Alvaro Cervera; Angel Chamorro
Journal:  Curr Cardiol Rev       Date:  2010-08

Review 7.  Risk factor management to prevent first stroke.

Authors:  Tatjana Rundek; Ralph L Sacco
Journal:  Neurol Clin       Date:  2008-11       Impact factor: 3.806

8.  Antithrombotic medication for cardioembolic stroke prevention.

Authors:  M Àngels Font; Jerzy Krupinski; Adrià Arboix
Journal:  Stroke Res Treat       Date:  2011-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.